Compare Inovio Pharmaceuticals Inc (INO) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Teradyne, Inc. trades at $369.02 (market cap $52.25B). The key difference: Teradyne, Inc. is far larger — about 585.3× Inovio Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.16% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TER | |
|---|---|---|
Market Cap | $89.27M | $52.25B |
Sector | Health | Technology |
52-Week High | $2.87 | $483.84 |
52-Week Low | $1.05 | $90.15 |
Enterprise Value | $60.28M | $52.08B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Teradyne (TER) trades at $334.23, up 3.68% on the day, with strong recent earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but benefits from high profitability margins (net income margin 22.55%) and consistent revenue growth, projected to reach $3.8B in 2026. Analysts maintain a bullish consensus with a $453.60 price target, citing AI infrastructure expansion and recent product launches as key catalysts.
Outlook remains positive given TER's strategic positioning in AI and semiconductor testing, though elevated valuation ratios (P/E 59.81) and technical bearishness pose near-term risks. Investment opportunity hinges on execution in high-growth AI segments, while risks include market volatility and competitive pressures in the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
